VTRS - Novo Nordisk underperforms as Viatris fights Wegovy patents
2023-10-01 12:00:03 ET
More on Novo Nordisk
- Viatris: Generic Semaglutide Could Become The Poor Man's Option For Weight Loss
- Novo Nordisk: DCF Analysis Suggests Significant Undervaluation
- Novo Nordisk: Catching The Falling Knife Now Could Really Hurt
- Viatris and Ocuphire Pharma announce FDA approval for eye drop formulation RYZUMVl
- Novo Nordisk inks AI-led drug discovery deal worth up to $2.7B
For further details see:
Novo Nordisk underperforms as Viatris fights Wegovy patents